EPIRUS Biopharmaceuticals Joins Biosimilars Forum to Help Educate Patients and Healthcare Providers on Importance of Biosimilars
November 05, 2015 08:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Nov. 05, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals to Release Third Quarter 2015 Financial Results and Provide Business Update
October 29, 2015 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Oct. 29, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through Acquisition of Bioceros
September 09, 2015 06:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
Combined companies’ product pipeline targets reference biologics with sales of $29 billion in 2014Pipeline expanded to include biosimilars to Soliris®, STELARA® and SIMPONI® Capabilities...